iTeos 2024 Strategic Priorities and Anticipated Milestones

  TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC

- Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s Phase 2 A2A-005 and EOS-984’s Phase 1 trial

- EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024

- Cash balance and investment balance of $644.9 million as of September 30, 2023 expected to provide runway through 2026

https://www.globenewswire.com/news-release/2024/01/08/2805279/0/en/iTeos-Announces-2024-Strategic-Priorities-and-Anticipated-Milestones.html